TY - JOUR
T1 - Left bundle branch area versus conventional pacing after transcatheter valve implant for aortic stenosis
T2 - The LATVIA study
AU - Dell'Era, Gabriele
AU - Baroni, Matteo
AU - Frontera, Antonio
AU - Ghiglieno, Chiara
AU - Carbonaro, Marco
AU - Penela, Diego
AU - Romano, Carmine
AU - Giordano, Federica
AU - Del Monaco, Guido
AU - Galimberti, Paola
AU - Mazzone, Patrizio
AU - Patti, Giuseppe
N1 - Publisher Copyright:
© 2024 Lippincott Williams and Wilkins. All rights reserved.
PY - 2024/6/1
Y1 - 2024/6/1
N2 - BackgroundAtrioventricular block (AVB) is a frequent complication in patients undergoing transcatheter aortic valve implantation (TAVI). Right apex ventricular pacing (RVP) represents the standard treatment but may induce cardiomyopathy over the long term. Left bundle branch area pacing (LBBAP) is a promising alternative, minimizing the risk of desynchrony. However, available evidence with LBBAP after TAVI is still low.ObjectiveTo assess the feasibility and safety of LBBAP for AVB post-TAVI compared with RVP.MethodsConsecutive patients developing AVB early after TAVI were enrolled between 1 January 2022 and 31 December 2022 at three high-volume hospitals and received LBBAP or RVP. Data on procedure and at short-term follow-up (at least 3 months) were collected.ResultsA total of 38 patients (61% men, mean age 83 ± 6 years) were included; 20 patients (53%) received LBBAP. Procedural success was obtained in all patients according to chosen pacing strategy. Electrical pacing performance at implant and after a mean follow-up of 4.2 ± 2.8 months was clinically equivalent for both pacing modalities. In the LBBAP group, procedural time was longer (70 ± 17 versus 58 ± 15 min in the RVP group, P = 0.02) and paced QRS was shorter (120 ± 19 versus 155 ± 12 ms at implant, P < 0.001; 119 ± 18 versus 157 ± 9 ms at follow-up, P < 0.001). Complication rates did not differ between the two groups.ConclusionIn patients with AVB after TAVI, LBBAP is feasible and safe, resulting in a narrow QRS duration, either acutely and during the follow-up, compared with RVP. Further studies are needed to evaluate if LBBAP reduces pacing-induced cardiomyopathy in this clinical setting.
AB - BackgroundAtrioventricular block (AVB) is a frequent complication in patients undergoing transcatheter aortic valve implantation (TAVI). Right apex ventricular pacing (RVP) represents the standard treatment but may induce cardiomyopathy over the long term. Left bundle branch area pacing (LBBAP) is a promising alternative, minimizing the risk of desynchrony. However, available evidence with LBBAP after TAVI is still low.ObjectiveTo assess the feasibility and safety of LBBAP for AVB post-TAVI compared with RVP.MethodsConsecutive patients developing AVB early after TAVI were enrolled between 1 January 2022 and 31 December 2022 at three high-volume hospitals and received LBBAP or RVP. Data on procedure and at short-term follow-up (at least 3 months) were collected.ResultsA total of 38 patients (61% men, mean age 83 ± 6 years) were included; 20 patients (53%) received LBBAP. Procedural success was obtained in all patients according to chosen pacing strategy. Electrical pacing performance at implant and after a mean follow-up of 4.2 ± 2.8 months was clinically equivalent for both pacing modalities. In the LBBAP group, procedural time was longer (70 ± 17 versus 58 ± 15 min in the RVP group, P = 0.02) and paced QRS was shorter (120 ± 19 versus 155 ± 12 ms at implant, P < 0.001; 119 ± 18 versus 157 ± 9 ms at follow-up, P < 0.001). Complication rates did not differ between the two groups.ConclusionIn patients with AVB after TAVI, LBBAP is feasible and safe, resulting in a narrow QRS duration, either acutely and during the follow-up, compared with RVP. Further studies are needed to evaluate if LBBAP reduces pacing-induced cardiomyopathy in this clinical setting.
KW - atrioventricular block
KW - conduction system pacing
KW - left bundle branch area pacing
KW - pacing-induced cardiomyopathy
KW - transcatheter aortic valve implantation
UR - http://www.scopus.com/inward/record.url?scp=85195026887&partnerID=8YFLogxK
U2 - 10.2459/JCM.0000000000001619
DO - 10.2459/JCM.0000000000001619
M3 - Article
SN - 1558-2027
VL - 25
SP - 450
EP - 456
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
IS - 6
ER -